



04-05-06

IFW
C-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bondarev

Serial No.: 10/758,329

Filed: January 15, 2004

Attorney Docket No.: 04-40018-US

TITLE: MODULATION OF LINE-1
REVERSE TRANSCRIPT ASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)(2)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

04/06/2006 WASFAW1 00000064 10758329

01 FC:1806

180.00 OP

This Information Disclosure Statement is being filed after the mailing date of a first office action. Therefore, the fee required under 37 C.F.R. §1.97(c)(2) (One Hundred and Eighty Dollars (\$180.00)) is enclosed. The Commissioner is hereby authorized to charge any payment of fees or credit any over-payment associated with this application to Deposit Account No. 18-0586.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10


EXPRESS MAIL Mailing Label Number: EV 699479008 US

Date of Deposit: April 4, 2006

I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL – POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450


Cody M. McAtee

(Name of person mailing paper.)



(Signature of person mailing paper.)

Respectfully submitted,



Nanda P.B.A. Kumar

Registration No. 44,853

REED SMITH LLP

P.O. Box 7990

Philadelphia, PA 19101-7990


(215) 241-7991

Attorney for Applicant

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
04-40018-US

SER. NO.
10/758,329



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Bondarev

FILING DATE

January 15, 2004

GROUP

1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA	5,539,082	7/23/1996	Nielsen et al.		
	AB	5,714,331	2/3/1998	Buchardt et al.		
	AC	5,719,262	2/17/1998	Buchardt et al.		
	AD	6,046,307	4/4/2000	Shay et al.		
	AE	6,194,206	02/27/2001	West et al.		
	AF	6,156,763	12/05/2000	Kerwin et al.		
	AG	6,294,332	9/25/2001	Chabot		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					
	BB					
	BC					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CA	De Clercq, "Recent developments in the chemotherapy of HIV infections", Pure & Appl. Chem., Vol. 70, No. 3, pp. 567-577, 1998.
	CB	Yamaguchi, et al., "Telomerase-inhibitory effects of the triphosphate derivatives of some biologically active nucleosides", Nucleic Acids Research Supplement No. 1, pp. 211-212, 2001.
	CC	Bisoffi, et al., "Inhibition of Human Telomerase by a Retrovirus Expressing Telomeric Antisense RNA", European Journal of Cancer, Vol. 34, No. 8, pp. 1242-1249, 1998.
	CD	Roth, et al., "Telomerase is limiting the growth of acute myeloid leukemia cells", Leukemia, 17, pp. 2410-2417, 2003.
	CE	Damm, et al., "A highly selective telomerase inhibitor limiting human cancer cell proliferation", The EMBO Journal, Vol. 20., No. 24, pp. 6958-6968, 2001.
	CF	GeneBank GI:5070620, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=5070620 .

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AH	6,723,712	4/20/2004	Bourhis et al.		
	AI					
	AJ					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BD					
	BE					
	BF					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CG	Kimberland, et al., "Full-length human L 1 insertions retain the capacity for high frequency retrotransposition in cultured cells", Human Molecular Genetics, 1999, Vol. 8, No. 8, pp. 1557-1560.
	CH	Dorafshar, et al., "Vascular Endothelial Growth Factor Inhibits Mitogen-Induced Vascular Smooth Muscle Cell Proliferation", Journal of Surgical Research, 114, pp. 179-186, 2003.
	CI	Yang, et al., "Effects of GM-CSF, IL-3, and GM-CSF/ IL-3 fusion protein on apoptosis of human myeloid leukemic cell line Tf-1 induced by irradiation", Acta Pharmacol Sin 2004 Jan; 25 (1): 68-75.
	CJ	Schwahn, et al., "Positional cloning of the gene for X-linked retinitis pigmentosa 2", Nature Genetics, Vol. 19, August 1998, pp. 327-332.
	CK	Holmes, et al., "A new retrotransposable human L1 element from the LRE2 locus on chromosome 1q produces a chimaeric insertion", Nature Genetics, Vol. 7, June 1994.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AK					
	AL					
	AM					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BG					
	BH					
	BI					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CL	Yoshida, et al., "Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy", Human Molecular Genetics, 1998, Vol. 7, No. 7, pp. 1129-1132.
	CM	Brouha, et al., "Evidence Consistent with Human L1 Retrotransposition in Maternal Meiosis I, Am J. Hum. Genet. Vol. 71, pp. 327-336, 2002.
	CN	Atlschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17 pp. 3389-3402, 1997.
	CO	Ahlquist, "RNA-Dependant RNA Polymerases, Viruses, and RNA Silencing", Science, Vol. 296 pp. 1270-1273, May 17, 2002.
	CP	Yeager, et al., "Telomerase-negative Immortalized Human Cells Contain a Novel Type of Promyelocytic Leukemia (PML) Body" Cancer Research, Vol. 59, pp. 4175-4179, September 1, 1999.
	CQ	Rudolph, et al., "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice", Cell, Vol. 96, pp. 710-712, March 5, 1999.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AN					
	AO					
	AP					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BJ					
	BK					
	BL					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CR	Wang, et al., "Prolonged and Inducible Transgene Expression in the Liver Using Gutless Adenovirus: A Potential Therapy for Liver Cancer", Gastroenterology, Vol. 126, pp. 278-289, 2004.
	CS	Bryan, et al., "Telomere Dynamics and Telomerase Activity In <i>In Vitro</i> Immortalised Human Cells, European Journal of Cancer, Vol. 33, No. 5, pp. 767-773, 1997.
	CT	Greider, et al., "Identification of a Specific Telomere Terminal Transferase Activity in Tetrahymena Extracts", Cell, Vol. 43, pp. 405-413, December 1985, (Part 1).
	CU	Kim, et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer", Science, Vol. 266, pp. 2011-2015, December 23, 1994.
	CV	Bryan, et al., "Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines", Nature Medicine, Vol. 3, No. 11, pp. 1271-1274, November 1997.
	CW	Kazazian, Jr., et al., "The impact of L1 retrotransposons on the human genome", Nature Genetics, Vol. 19, pp. 19-24, May 1998.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AQ					
	AR					
	AS					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BM					
	BN					
	BO					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CX	Nozawa, et al., "In vitro expansion of mammalian telomere repeats by DNA polymerase α -primase", Nucleic Acids Research, Vol. 28, No. 16, pp. 3117-3124, 2000.
	CY	Allshire, et al., "Human telomeres contain at least three types of G-rich repeat distributed non-randomly", Nucleic Acids Research, Vol. 17, No. 12, pp. 4611-4627, 1989.
	CZ	Hahn, et al., "Inhibition of telomerase limits the growth of human cancer cells", Nature Medicine, Vol. 5, No. 10, pp. 1164-1170, October 1999.
	CCA	Bryan, et al., "Telomere elongation in immortal human cells without detectable telomerase activity", The EMBO Journal, Vol. 14, No. 17, pp. 4240-4248, 1995.
	CCB	Gupta, et al., "Development of Retinoblastoma in the Absence of Telomerase Activity", Journal of the National Cancer Institute, Vol. 88, No. 16, August 21, 1996.
	CCC	Dunham, et al., "Telomere maintenance by recombination in human cells", Nature Genetics, Vol. 26, pp. 447-450, December 2000.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AT					
	AU					
	AV					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BP					
	BQ					
	BR					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCD	Clements, et al., "The human LINE-1 reverse transcriptase: effect of deletions outside the common reverse transcriptase domain", Nucleic Acids Research, Vol. 26, No. 15, pp. 3528-3535, 1998.
	CCE	Skowronski et al., "Expression of a cytoplasmic LINE-1 transcript is regulated in a human teratocarcinoma cell line", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 6050-6054, September 1985.
	CCF	Moran et al., "High Frequency Retrotransposition in Cultured Mammalian Cells", Cell, Vol. 87, pp. 917-927, November 29, 1996.
	CCG	Murakami, et al., "Inhibition of Telomerase Activity and Cell Proliferation by a Reverse Transcriptase Inhibitor in Gynaecological Cancer Cell Lines, European Journal of Cancer, Vol. 35, No. 6, pp. 1027-1034, 1999.
	CCH	Rufer, et al., "Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry", Nature Biotechnology, Vol. 16, p. 743-747, August 1998.
	CCI	Hultdin, et al., "Telomere analysis by fluorescence <i>in situ</i> hybridization and flow cytometry", Nucleic Acids Research, Vol. 26, No. 16, pp. 3651-3656, 1998.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AW					
	AX					
	AY					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BS					
	BT					
	BU					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCJ	Perrem, et al. "Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids", Oncogene, Vol. 18, pp. 3383-3390, 1999.
	CCK	Guiducci, et al., "Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability", Oncogene, Vol. 20, pp. 714-725, 2001.
	CCL	Craig, et al., "Effects of adenovirus-mediated p16 ^{INK4A} expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells", Oncogene, Vol. 16, pp. 265-272, 1998.
	CCM	Ostertag, et al., "Determination of L 1 retrotransposition kinetics in cultured cells", Nucleic Acids Research, Vol. 28, No. 6, pp. 1418-1423, 2000.
	CCN	Kuo, et al., "Expression of Transposon LINE-1 is Relatively Human-Specific and Function of the Transcripts May Be Proliferation-Essential, Biochemical and Biophysical Research Communications, 253, pp. 566-570 (1998).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT Bondarev	
	FILING DATE January 15, 2004	GROUP 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AW					
	AX					
	AY					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BS					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCO	Hernandez, et al., "Systemic treatment modalities in the management of AIDS-related Kaposi's sarcoma", Journal of the European Academy of the Dermatology and Venereology, 9, 1997, pp. 44-49.
	CCP	Poirier, et al., "Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs", Toxicology and Applied Pharmacology, 199, 2004, pp. 151-161.
	CCQ	Langford, et al., "Regression of oral Kaposi's sarcoma in a case of AIDS on Zidovudine (AZT), British Journal of Dermatology, vol. 120, 1989, pp. 709-713.
	CCR	Ofelia, et al., "Transplacental Effects of 3'-Azido-2', 3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and Monkeys", Journal of the National Cancer Institute, Vol. 89, No. 21, November 5, 1997, pp. 1602-1618.
	CCS	Pluda, et al., "Parameters Affecting the Development of Non-Hodgkin's Lymphoma in Patients With Severe Human Immunodeficiency Virus Infection Receiving Antiretroviral Therapy", Journal of Clinical Oncology, Vol. 11, No. 6, June 1993, pp. 1099-1107.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.